

Curriculum Vita



First Name: Afsane

Last Name: Vaezi

PhD in Medical Mycology

Department of Medical Laboratory Science, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

Email: vaeziafsane@gmail.com

Educational Background:

2011-2013: MSc: Medical Mycology. Mazandaran University of Medical Sciences, Sari, Iran

2014-2018: PhD student in medical mycology, Departments of Medical Mycology, Mazandaran University of Medical Sciences, Sari-Iran

Research experiences and fields of interest:

Epidemiological surveillance study.

In vitro activities of antimicrobials (alone or in combination) against clinical fungi based on CLSI broth microdilution, E test and checkerboard assay.

In vivo antifungal activities in murine model infection.

Early diagnosis assays based on conventional e.g., micro-culture and molecular method.

Evolution of pathogenicity of fungal.

The mechanism of drug resistance.

The evolution of azole resistance and measures to prevent the emergence of multiple-azole-resistant.

Honors and Awards:

The top-rated PhD entrance exam in 2014 in Iran. (Number one).

The member of Iran's National Elites Foundation.

Top researcher at Mazandaran university medical sciences January, 2018.

Top student in the university (Top talent in the university).

Member of the European Society of Clinical Microbiology and Infection Disease (ESCMID).

FEMS young investigators travel award worth 600 Euro for an outstanding presentation at the 7th Conference of Medical Microbiology (FEMS) July 9-13, 2017, Valencia, Spain.

ESCMID Observership, 1700 EUR (ID1164), France, Nacker Hospital for one month.

Top one percent most cited researcher in ESI 2021.

Publications

1. Vaezi A, Walther G, Kurzai O, Mahdi D, Dadashzade M, Nasri E, Diba K, Badali H, Fakhim H. Frequency of occurrence, seasonal variation and antifungal susceptibility of opportunistic Mucorales isolated from hospital soils in Iran. *Mycoses*. 2021 Apr 9. <https://doi.org/10.1111/myc.13283>.
2. Vaezi A, Fakhim H, Abtahian Z, Geramishoar M, Khodavaisy S, Alizadeh A, Meis JF, Badali H. Frequency and geographic distribution of CARD9 mutations in patients with severe fungal infections. *Front Microbiol*. 2018; doi: 10.3389/fmicb.2018.02434.
3. Afsane Vaezi, Hamed Fakhim, Macit Ilkit, Leila Faeli, Mahdi Fakhar, Vahid Alinejad, Nathan P. Wiederhold & Hamid Badali. Rapid and low-cost culture-based method for diagnosis of mucormycosis using a mouse model. *Front Microbiol*. 2020. Doi: 10.3389/fmicb.2020.00440.
4. Vaezi A, Fakhim H, Arastehfar A, Shokohi T, Hedayati MT, Khodavaisy S, Rezaei-Matehkolaei A, Badiee P, Hagen F, Lass-Flörl C, Dannaoui E, Meis JF, Badali H. In vitro antifungal activity of amphotericin B and eleven comparators against *Aspergillus terreus* species complex. *Mycoses*. 2017 Oct 24. doi: 10.1111/myc.12716. [Epub ahead of print] PubMed PMID: 29064123.
5. Vaezi A, Moazeni M, Rahimi MT, de Hoog S, Badali H. Mucormycosis in Iran: a systematic review. *Mycoses*. 2015, doi:10.1111/myc.12474.
6. Fakhim H, Badali H, Dannaoui E, Nasirian M, Jahangiri F, Raei M, Vaseghi N, Ahmadikia K, Vaezi A. Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates

-
- of Aspergillus Species. J Mycol Med. 2022 Nov;32(4):101310. doi: 10.1016/j.mycmed.2022.101310. Epub 2022 Jul 14. PMID: 35907396.
7. Vaezi A, Moghadaszadeh M, Nasri E, Gharibi S, Diba K, Matkowski A, Fakhim H. In vitro activity of juglone (5-hydroxy-1,4-naphthoquinone) against both fluconazole-resistant and susceptible *Candida* isolates. Rev Iberoam Micol. 2022 Apr-Jun;39(2):50-53. doi: 10.1016/j.riam.2022.01.004. Epub 2022 Jun 11. PMID: 35701335.
8. Nasri E, Vaezi A, Shelerangkon M, Rizi MH, Ghafel S, Abbasi K, Badali H, Fakhim H. Catheter-associated blood stream infections due to *Candida pararugosa* in a patient with acute myeloid leukemia: A case report. Braz J Microbiol. 2023 Jun;54(2):891-895. doi: 10.1007/s42770-023-00985-5. Epub 2023 May 8. PMID: 37157053; PMCID: PMC10234983.
9. Arastehfar A, Fang W, Badali H, Vaezi A, Jiang W, Liao W, et al. Low-Cost Identification for the Global Spreading Multi-drug Resistant Superbug Fungus, *Candida auris* and its phylogenetic relatives. Front Microbiol. 2018; 9:1119. doi: 10.3389/fmicb.2018.01119.
10. K. Pakshir , H. Fakhim , A. Vaezi, J.F. Meis, M. Mahmoodi, K. Zomorodian, J. Javidnia, S. Ansari, F. Hagen, H. Badali. Molecular epidemiology of environmental *Cryptococcus* species isolates based on amplified fragment length polymorphism. Journal de Mycologie Médicale 28 (2018) 599–605. <https://doi.org/10.1016/j.mycmed.2018.09.005>.
11. Diba K, Makhdoomi K, Nasri E, Vaezi A, Javidnia J, Jabbari Gharabagh D, et al. Emerging *Candida* species isolated from renal transplant recipients: Species distribution and susceptibility profiles. Microbial Pathogenesis. 2018. Doi: 10.1016/j.micpath.2018.09.026.
- 12.
13. Fakhim H, Vaezi A, Javidnia J, Nasri E, Mahdi D, Diba K, Badali H. *Candida africana* vulvovaginitis: Prevalence and geographical distribution. J Mycol Med. 2020 Apr 5:100966. doi: 10.1016/j.mycmed.2020.100966.
14. Fakhim, H., Vaezi A, A., Dannaoui, E., et al. In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of *Aspergillus fumigatus* from different geographical regions. Diagnostic Microbiology and Infectious Disease. 2018.
15. Fakhim H, Emami S, Vaezi A, Hashemi SM, Faeli L, Diba K, et al. In Vitro Activities of Novel Azole Compounds (ATTAF-1 and ATTAF-2) Against Fluconazole-Susceptible and -Resistant Isolates of *Candida* species. Antimicrob Agents Chemother. 2016.
16. Fakhim H, Vaezi A, Dannaoui E, Chowdhary A, Nasiry D, Faeli L, Meis JF, Badali H.
-

-
- Comparative virulence of *Candida auris* with *Candida haemulonii*, *Candida glabrata* and *Candida albicans* in a murine model. *Mycoses*. 10.1111/myc.12754.
17. Badali H, Vaezi A, Haghani I, Yazdanparast SA, Hedayati MT, Mousavi B, et al. Environmental study of azole-resistant *Aspergillus fumigatus* with TR34/L98H mutations in the cyp51A gene in Iran. *Mycoses*. 2013;56(6):659-63.
 18. Badali, Fakhim H, Zarei F, Nabili M, Vaezi A, Poorzad N, Dolatabadi S, Mirhendi H, In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of *Aspergillus Nigri* Complex. *Mycopathologia*, DOI 10.1007/s11046-015-9968-0.
 19. Vaezi A, Fakhim H, Khodavaisy S, Alizadehd A, Nazeri M, Razzaghif R, Boekhout T, Badali H. Epidemiological and mycological characteristics of candidemia in Iran: A systematic review and meta-analysis. *J Mycol Med* 2017.
 20. Vaezi A, Fakhim H, Javidnia J, Mohsenid S, Nourbakhsh F, Badali H. Pesticide behavior in Paddy fields and development of azole resistance *Aspergillus fumigatus*: should we be concerned? *de Mycologia* 2017. <https://doi.org/10.1016/j.mycmed.2017.12.007>.
 21. Hamed Fakhim, Shirin Irani, Zeynab Yassin, Hamid Badali, Elahe Nasri, Yasser Nasoori, Seyedhadi Samimiardestani, Saleh Mohebbi, Mojtaba Mohammadi Ardehali, Pegah Alizadeh Pahlavan, Mohammadreza Firouzifar, Ardavan Tajdini, Samira Ahadi, Afsane Vaezi,
 22. Features and evaluation of mucormycosis in COVID-19 patients from two referral hospitals in Iran, *Journal of Medical Mycology*, <https://doi.org/10.1016/j.mycmed.2024.101480>.
 23. Motahari K, Badali H, Hashemi SM, Fakhim H, Mirzaei H, Vaezi A, et al. Discovery of benzylthio analogs of fluconazole as potent antifungal agents. 2018<https://doi.org/10.4155/fmc-2017-0295>.
 24. In Vitro Interactions of Echinocandins with Triazoles Against Multidrug-Resistant *Candida auris*. Fakhim H, Chowdhary A, Prakash A, Vaezi A, Dannaoui A, Meis J, Badali H. *Antimicrob Agents Chemother*. 2017. 24;61(11). pii: e01056-17. doi: 10.1128/AAC.01056-17.
 25. Falahatinejad M, Vaezi A, Fakhim H, Abastabar M, Shokohi T, Zahedi N, Ansari S, Meis JF, Badali H. Use of CSP typing for genotyping of azole-resistant and -susceptible *Aspergillus fumigatus* isolates in Iran. *Mycoses*. 2017 Oct 24. doi:10.1111/myc.12717. [Epub ahead of print] PubMed PMID: 29064130.
 26. Hamed Fakhim, Afsane Vaezi, Hamid Morovati, Azadeh Bandegani, Kiana Abbasi, Saeed Emami, Davood Nasiry, Seyedeh Mahdieh Hashemi, Fatemeh Ahangarkani, Hamid Badali,
 27. In-vivo efficiency of the novel azole compounds (ATTAF-1 and ATTAF-2) against systemic
-

-
- candidiasis in a murine model, Journal of Medical Mycology,<https://doi.org/10.1016/j.mycmed.2023.101437>.
28. In Vitro Activity of Luliconazole, Lanconazole, and Efinaconazole Compared with Five Antifungal Drugs Against Melanized Fungi and Relatives. Shokoohi GR, Badali H, Mirhendi H, Ansari S, Rezaei-Matehkolaee A, Ahmadi B, Vaezi A, Alshahni MM, Koichi Makimura. *Antimicrob Agents Chemother*. 2017.
 29. Rezai MS, Vaezi A, Fakhim H, Soleimani A, Mohammad Jafari H, M. ohseni S, Badali H. Successful treatment with caspofungin of candiduria in a child with Wilms tumor; review of literature. *J Mycol Med*. 2017 Feb 7. pii: S1156-5233(16) 30200-1.doi: 10.1016/j.mycmed.2017.01.006.
 30. Elahe Nasri, Hamed Fakhim, Afsane Vaezi, Soheila Khalilzadeh, Fatemeh Ahangarkani, Melika Laal kargar, Zahra Abtahian, Hamid Badali. Airway Colonization by Candida and Aspergillus species in Iranian Cystic Fibrosis Patients. *Mycoses*. 2019 Jan 25. doi: 10.1111/myc.12898.
 31. Nasri, E., Vaezi, A., Falahatinejad, M. et al. Species distribution and susceptibility profiles of oral candidiasis in hematological malignancy and solid tumor patients. *Braz J Microbiol* 54, 143–149 (2023). <https://doi.org/10.1007/s42770-022-00863-6>.
 32. Badali H, Al-Hatmi AMS, Fakhim H, Moghaddasi A, Khodavaisy S, Vaezi A, Ahangarkani F, de Hoog GS, Meis JF. In vitro activity of nine antifungal agents against a global collection of *Hortaea werneckii* isolates, the agent of tinea nigra. *Int J Antimicrob Agents*. 2019 Jul;54(1):95-98. doi: 10.1016/j.ijantimicag.2019.05.006. Epub 2019 May 7. PubMed PMID: 31071468.
 33. Mohammadi R, Mohammadi A, Ashtari F, Khorvash F, Hakamifard A, Vaezi A, Javidnia J, Meis JF, Badali H. Cerebral phaeohyphomycosis due to *Rhinocladiella mackenziei* in Persian Gulf region: A case and review. *Mycoses*. 2017. doi:10.1111/myc.12734.
 34. Hamed Fakhim, Afsane Vaezi, Javad Javidnia, Elahe Nasri, Diman Mahdi, Kambiz Diba, Hamid Badali. *Candida africana Vulvovaginitis: Prevalence and Geographical Distribution*. *Journal de Mycologie Médicale*. (2020).
 35. Zaynab Sadeghi-Ghadi, Afsane Vaezi, fatemeh ahangarkani, Pedram Ebrahimnejad. Hamid Badali. CUR-QUE-NV-WH: A nanovesicle with potent in vitro activity against resistant Aspergillus and Candida species. (2020).
 36. Nasri, E., Shoaei, P., Vakili, B., Mirhendi, H., Sadeghi, S., Hajiahmadi, S., Sadeghi, A., Vaezi, A., Badali, H., Fakhim, H. Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute
-

-
- Myeloid Leukemia in Iran. Mycopathologia (2020). <https://doi.org/10.1007/s11046-020-00493-2>.
37. Kachuei R, Badali H, Vaezi A, Jafari NJ, Ahmadikia K, Kord M, Aala F, Al-Hatmi AM, Khodavaisy S. Fatal necrotising cutaneous mucormycosis due to novel Saksenaea species: a case study. *J Wound Care.* 2021 Jun 2;30(6):465-468. doi: 10.12968/jowc.2021.30.6.465. PMID: 34121440.
38. Nasri E, Fakhim H, Salahi M, Ghafel S, Pourjam S, Darakhshandeh A, Kassaian N, Sadeghi S, Ataei B, Javanmard SH, Vaezi A. Efficacy of Hydroxychloroquine in Pre-exposure Severe Acute Respiratory Syndrome Coronavirus 2 Prophylaxis among High-Risk HealthCare Workers: A Multicenter Study. *Adv Biomed Res.* 2023 Jan 27;12:3. doi: 10.4103/abr.abr_104_21. PMID: 36926426; PMCID: PMC10012028.
39. Badali H, Vaezi A, Aslani N, Zahedi N, Shiran MR. Overview of voriconazole pharmacokinetics and pharmacodynamic parameters. *J Mazandaran Univ Med Sci* 2016; 26(136): 225-235 (Persian). Scopus
40. Rezai MS, Vaezi A, Fakhim H, Mohseni S, Faeli L, Badali H. *Candida* Urinary Tract Infections; Treatment Protocol. *J Mazandaran Univ Med Sci* 2017; 26 (145): 421-432 (Persian). Scopus
41. Vaezi A, Haghani I, Mohammad Davoudi M, Mousavi B, Ansari S, Noshak M, et al. Azole Resistance in *Aspergillus fumigatus* Isolates. *J Mazand Univ Med Sci* 2013; 23(103): 121-137 (Persian). 2013;23(103):121-37. Scopus
42. Aslani N, Nabili M, Zahedi N, Vaezi A, khodavaisy S, Badali H. The Role of Pattern Recognition Receptors (PRR) in Human Candidiasis. *J Mazand Univ Med Sci* 2014; 24(114): 224-240 (Persian). Scopus
43. Vaezi, A., Mardani, M., Fakhim, H., Hedayat Yaghoobi, M., Abtahian, Z., Nasri, E., et al. (2018). Severe disseminated phaeohyphomycosis in a patient with inherited CARD9 deficiency. *Arch. Clin. Infect. Dis.* doi: 10.1093/infdis/jiu412.ISI
44. A. Ghorbani, A. Sadrzadeh, E. Habibi, K. Dadgar, J. Akbari, M. Moosazadeh, H. Bakhshi, F. Ahangarkani, A. Vaezi (Corresponding Author). Efficacy of Camellia sinensis extract against *Candida* species in patients with denture stomatitis. DOI: <https://doi.org/10.18502/cmm.4.3.174>.ISI.
45. Afsane Vaezi, Hamid Badali, Hamed Fakhim, Elahe Nasri, Mojtaba Hedayat Yaghoobi. A Review of Esophagitis Due to *Candida* Species in Human Immunodeficiency Virus (HIV) Infected Patients. A Review of Esophagitis Due to *Candida* Species in Human Immunodeficiency Virus
-

-
- (HIV) Infected Patients. Doi. 10.15171/ijep.2018.23.
46. Nasri E, Mirhendi H, Ataei B, Vaezi A, Sadeghi S, et al. (2020) Recurrent COVID-19 Pneumonia in Chronic Lymphocytic Leukemia Patient. Arch ClinMicrobiol Vol. 11 No. 4:120. doi: 10.36648/1989-8436.11.4.120.
47. Leila Masumi, Hamed Fakhim, Afsane Vaezi, Mohammad Pourhassan-Moghaddam, Abbas Ebrahimi-Kalan, Nosratollah Zarghami. Strategies for Isothermal Amplification of Nucleic Acids: are they Ready to be Applied in Point of Care Diagnosis of Mycosis? Volume 11, Issue 3, 2021, 10559 – 10571. IF: 0.7
48. Hamed Fakhim, Elahe Nasri, Shima Aboutalebian, Sahar Golipour, Mahnaz Nikaeen, Afsane Vaezi, Somayeh Mousavi, Sama Faramarzi, Armin Farhang, Shaghayegh Haghjooy Javanmard, Mehrdad Salahi, Ali Derakhshandeh, Kazem Ahmadikia8 & Hossein Mirhendi. Asymptomatic carriers of coronavirus disease 2019 among healthcare workers in Isfahan, Iran. <https://www.futuremedicine.com/doi/10.2217/fvl-2020-0224>.
49. Nasri E , Fakhim H, Jafari Sales A , Bannazadeh Baghi H , Vaezi A, et al. Prevalence of Human T-Lymphotropic Virus Type 1 in Brain-Dead Organ Donors. Arch Clin Infect Dis. 2022;17(1):e116005. <https://doi.org/10.5812/archcid-116005>.

Congress Presentations

I published approx.33 abstracts in both international (18) and national conferences (15). I had oral presentation in ISHAM 2018 with the following title; Molecular epidemiology and antifungal susceptibility profiles of Aspergillus terreus in Iran. 30 June -4 July 2018. Amsterdam, ISHAM Congress. The Netherland. ORAL.

My abstract was also accepted as an oral presentation at ISHAM Congress 2022 in India under the title: Yeast Microbiome in patients with inflammatory bowel disease (IBD).

Professional Memberships

- 1) Member of the European Society of Clinical Microbiology and Infection Disease (ESCMID).
- 2) FEMS young investigators travel award worth 600 Euro for an outstanding presentation at the 7th Conference of Medical Microbiology (FEMS) July 9-13, 2017, Valencia, Spain.
- 3) ESCMID observership, 1700 EUR (ID1164), France, Nacker Hospital for one month
- 4) Member of the Iranian Society of Mycology

Others

- As a reviewer for 34 international journals including, frontiers in Mycoses, Microbiology, Mycopathologia, Virulence, Plos One, Frontier in microbiology, Frontiers in Cellular and Infection Microbiology, Frontiers in Genetics, BMC Infectious Diseases, Microbiological Research, American Journal of Infection Control, Clinical case report, Clinical Epidemiology, Infection and Drug Resistance, Cureus, Reports in Medical Imaging and International Medical Case Reports Journal, Current Medical Mycology, Journal of Wound Care, Process Biochemistry and Gene Reports.

- To submit and accept 250 genes in NCBI (gene bank). Between accession numbers MF185011 and MF185091, KY216167 and KY238199, MT603890 and MT603967.